PhotoPharmics expands its board as its fully enrolled Phase 3 Parkinson’s trial nears top-line results. New directors deepen clinical, regulatory, and capital-markets expertise as the company prepares for FDA submission and strategic partnerships.
American Fork, Utah - December 4, 2025
PhotoPharmics, the American Fork–based company developing photo-neuromodulation therapies for neurodegenerative disease, has added two seasoned industry leaders to its board just as it crosses a major clinical milestone and prepares for a decisive year ahead.
The additions come at a moment when the company is transitioning from execution to strategy: full enrollment of its Phase 3 Light for PD trial, imminent data analysis, regulatory planning, and the launch of a formal partnering process with top investment banks.
Trial Hits Enrollment Target
On November 5, the company announced it had surpassed its enrollment goal with 350 participants in Light for PD, its pivotal, six-month randomized, double-blind, placebo-controlled Phase 3 trial of the Celeste® device. The first-of-its-kind study is fully remote, conducted through a decentralized telemedicine model. Participants use Celeste at home while engaging with study teams over secure video visits.
CEO Kent Savage called the enrollment milestone “remarkable” and underscored the significance for the Parkinson’s community. The design is unusual for a pivotal device trial: rigorous, multi-site methodology delivered entirely in patients’ homes. CSO Dan Adams emphasized that the remote model has matched traditional, site-based trial standards while expanding access.
Top-line results are expected in Q2 2026, followed by an FDA submission planned for July 2026. Celeste already holds Breakthrough Device designation, signaling the agency’s view that it may offer meaningful improvement over existing options.
Celeste delivers calibrated light through the eyes to activate retinal cells that influence brain regions governing circadian rhythms, alertness, mood, cognition, and activity. By restoring this retinal-to-brain signaling, the therapy is designed to address the non-motor symptoms that degrade quality of life for people with Parkinson’s—sleep disruption, fatigue, apathy, mood disorders, cognitive issues—which in turn can improve motor function. If successful, it could become the first device therapy to meaningfully target this broad symptom cluster.
New Board Appointments Signal Next-Stage Preparation
To navigate the stretch between pivotal data, regulatory filings, and potential commercialization, PhotoPharmics has appointed two notable figures:
W. James W. Tozer, Jr. — Series B Director
A veteran investor, banker, and operator with more than 30 years of capital markets and governance experience. Tozer is the company’s largest Series B investor and second-largest investor overall.
Albert Agro, PhD — Independent Director
CEO of Jocasta Neuroscience and a former clinical and regulatory leader at Cynapsus, where he co-led the process that culminated in Sunovion’s $850 million acquisition of its sublingual apomorphine program. His background spans clinical development, regulatory strategy, and complex biotech transactions.
The two join the company’s continuing board members:
Together, they bring the mix of clinical, regulatory, commercial, and capital-market experience the company needs as it moves into a high-stakes period.
PhotoPharmics is initiating strategic partnering discussions with top investment banks while advancing its regulatory strategy and preparing for commercial pathways. The company’s IP estate—67 issued patents across 29 territories—provides considerable protection as it approaches market decisions.
Savage says the board expansion reflects the gravity of the moment:
“Jim and Albert bring decades of experience in clinical development, corporate strategy, operational execution, and international partnering—precisely the guidance we need as we prepare for the results of our FDA pivotal study and the next phase of PhotoPharmics’ growth.”
Learn more at www.photopharmics.com